References:
1. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis
Cochrane Cystic Fibrosis and Genetic Disorders Group, editor. Cochrane
Database of Systematic Reviews. 2018 [accessed 2021 Jul 14];2018(9).
https://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001506.pub4.
doi:10.1002/14651858.CD001506.pub4
2. House SA, Gadomski AM, Ralston SL. Evaluating the Placebo Status of
Nebulized Normal Saline in Patients With Acute Viral Bronchiolitis: A
Systematic Review and Meta-analysis. JAMA Pediatrics. 2020;174(3):250.
doi:10.1001/jamapediatrics.2019.5195
3. Khan SY, O’Driscoll BR. Is nebulized saline a placebo in COPD? BMC
Pulmonary Medicine. 2004;4(1):9. doi:10.1186/1471-2466-4-9
4. Chalmers JD, Aliberti S, Polverino E, Vendrell M, Crichton M,
Loebinger M, Dimakou K, Clifton I, van der Eerden M, Rohde G, et al. The
EMBARC European Bronchiectasis Registry: protocol for an international
observational study. ERJ Open Research. 2016;2(1):00081–02015.
doi:10.1183/23120541.00081-2015